文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

恰加斯心肌病心肌纤维化的长期预后价值

Long-Term Prognostic Value of Myocardial Fibrosis in Patients With Chagas Cardiomyopathy.
PubMed 文献 · J Am Coll Cardiol · 2018-01-01

本研究回顾性纳入130例曾接受心脏磁共振(CMR)评估的恰加斯心肌病患者,随访中位5.05年,评估心肌纤维化(MF)对复合硬终点及全因死亡的预测价值。结果显示MF在76.1%患者中存在,作为连续变量和分类变量(MF≥12.3 g)均独立于Rassi风险评分预测复合终点,连续变量也独立预测全因死亡。

要点

  • 恰加斯心肌病患者中CMR检出MF者占76.1%,平均MF质量15.2±16.5 g。
  • MF作为连续变量独立预测复合硬终点(aHR 1.031)和全因死亡(aHR 1.028)。
  • MF≥12.3 g独立预测复合终点(aHR 2.107),独立于Rassi风险评分。

核心结论

  • 心肌纤维化是恰加斯心肌病患者不良结局的独立预测因子。
  • CMR评估MF可能有助于该人群的风险分层并指导治疗。

研究设计与样本

  • 回顾性纳入130例既往接受CMR评估的恰加斯心肌病患者,回顾性获取临床随访。
  • 主要终点为全因死亡、心脏移植、ICD抗心动过速起搏或适当电击、及复苏性心脏性猝死的复合终点;次要终点为全因死亡。

主要发现

  • 中位随访5.05年,58例(44.6%)达到复合终点,45例(34.6%)死亡。
  • MF作为连续变量与主要终点相关(校正HR 1.031;95%CI 1.013–1.049;p=0.001)。
  • MF≥12.3 g与主要终点相关(校正HR 2.107;95%CI 1.111–3.994;p=0.022),独立于Rassi风险评分。
  • MF作为连续变量与全因死亡相关(校正HR 1.028;95%CI 1.005–1.051;p=0.017),独立于Rassi风险评分。

临床怎么用

  • 对恰加斯心肌病患者可考虑使用CMR评估心肌纤维化以改善风险分层。
  • MF质量及是否≥12.3 g可为临床决策提供参考,但需结合整体评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Myocardial fibrosis (MF) according to cardiac magnetic resonance (CMR) is a frequent finding in Chagas cardiomyopathy and has been associated with risk factors of poor outcome. OBJECTIVES: The goal of this study was to determine the prognostic value of MF in predicting combined hard events or all-cause mortality. METHODS: Patients with Chagas cardiomyopathy who had a previous CMR evaluation were included, and clinical follow-up was retrospectively obtained. The primary outcome was a combination of all-cause mortality, heart transplantation, antitachycardia pacing or appropriate shock from an implantable cardioverter-defibrillator, and aborted sudden cardiac death; the secondary outcome was all-cause mortality. RESULTS: A total of 130 patients were included; mean age was 53.6 ± 11.5 years, and 53.9% were female. The majority of patients reported no symptoms of heart failure or arrhythmia, but electrocardiographic and echocardiographic abnormalities were common. On CMR, left ventricular dilatation and dysfunction were frequent, and MF was found in 76.1%, with a mean mass of 15.2 ± 16.5 g. Over a median follow-up of 5.05 years, 58 (44.6%) patients reached the combined endpoint, and 45 (34.6%) patients died. MF was associated with the primary outcome as a continuous variable (adjusted hazard ratio: 1.031; 95% CI: 1.013 to 1.049; p = 0.001) and as a categorical variable (MF ≥12.3 g) (adjusted hazard ratio: 2.107; 95% CI: 1.111 to 3.994; p = 0.022), independently from the Rassi risk score. MF expressed as a continuous variable was also associated with all-cause mortality (adjusted hazard ratio: 1.028; 95% CI: 1.005 to 1.051; p = 0.017) independently from the Rassi risk score. CONCLUSIONS: MF is an independent predictor of adverse outcome in Chagas cardiomyopathy. Our data may support the use of CMR in better risk-stratifying this population and possibly guiding therapy.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Senra T, Ianni BM, Costa ACP, et al. Long-Term Prognostic Value of Myocardial Fibrosis in Patients With Chagas Cardiomyopathy. J Am Coll Cardiol. 2018. PMID: 30466515. doi:10.1016/j.jacc.2018.08.2195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。